Pricing Log in Create free account

ArriVent BioPharma, Inc. (AVBP) vs Design Therapeutics, Inc. (DSGN)

ArriVent BioPharma, Inc. and Design Therapeutics, Inc. are both Biotechnology companies. ArriVent BioPharma, Inc. and Design Therapeutics, Inc. are of similar size ($605.2M and $603.0M). Across the 8 metrics below, Design Therapeutics, Inc. leads on 6 and ArriVent BioPharma, Inc. on 2.

Valuation

Metric AVBP DSGN Biotechnology median
P/E n/m n/m 10.60
P/S n/m 2,842.20 9.40
P/B 1.77 3.18 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 1,919.15 9.02
Earnings yield (26.92%) (11.79%) (32.88%)
Free cash flow yield (22.81%) (9.24%) (23.13%)

Profitability

Metric AVBP DSGN Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (53.10%) (36.87%) (51.96%)
Return on assets (49.30%) (34.57%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AVBP DSGN Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (68.75%) (38.64%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AVBP DSGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.16 16.78 4.97
Net debt to EBITDA 1.73 2.68 1.01

Dividend

Metric AVBP DSGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AVBP DSGN Biotechnology median
Market cap 603.03m 605.16m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack